These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 23508978)

  • 1. Dyslipidemia and non-alcoholic fatty liver disease.
    Manickam P; Sudhakar R
    Dig Dis Sci; 2013 May; 58(5):1435. PubMed ID: 23508978
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognosis and staging of non-alcoholic fatty liver disease.
    Jepsen P; Grønbæk H
    BMJ; 2011 Nov; 343():d7302. PubMed ID: 22102440
    [No Abstract]   [Full Text] [Related]  

  • 3. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study.
    Lazo M; Hernaez R; Bonekamp S; Kamel IR; Brancati FL; Guallar E; Clark JM
    BMJ; 2011 Nov; 343():d6891. PubMed ID: 22102439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histological characteristics and prognosis in patients with fatty liver.
    Dam-Larsen S; Franzmann MB; Christoffersen P; Larsen K; Becker U; Bendtsen F
    Scand J Gastroenterol; 2005 Apr; 40(4):460-7. PubMed ID: 16028442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognosis of patients with a diagnosis of fatty liver--a registry-based cohort study.
    Jepsen P; Vilstrup H; Mellemkjaer L; Thulstrup AM; Olsen JH; Baron JA; Sørensen HT
    Hepatogastroenterology; 2003; 50(54):2101-4. PubMed ID: 14696473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Non-alcoholic fatty liver disease in dyslipidemia and insulin resistance: similarities and differences; differential approach to therapy].
    Lazebnik LB; Zvenigorodskaia LA; Egorova EG; Mel'nikova NV; Khomeriki SG
    Eksp Klin Gastroenterol; 2009; (8):4-11. PubMed ID: 20469672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Fatty liver: frequent and not completely harmless].
    Lang C; Georgi A; Gubler C
    Praxis (Bern 1994); 2013 Sep; 102(18):1089-101. PubMed ID: 24005067
    [No Abstract]   [Full Text] [Related]  

  • 8. Alcohol abstinence in alcoholic liver disease.
    Martini GA; Teschke R
    Acta Med Scand Suppl; 1985; 703():185-94. PubMed ID: 3004114
    [No Abstract]   [Full Text] [Related]  

  • 9. Impacts of types and degree of obesity on non-alcoholic fatty liver disease and related dyslipidemia in Chinese school-age children?
    Meng L; Luo N; Mi J
    Biomed Environ Sci; 2011 Feb; 24(1):22-30. PubMed ID: 21440836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Will the increased prevalence of nonalcoholic steatohepatitis (NASH) in the age of better hepatitis C virus therapy make NASH the deadlier disease?
    Rinella ME
    Hepatology; 2011 Oct; 54(4):1118-20. PubMed ID: 21956705
    [No Abstract]   [Full Text] [Related]  

  • 11. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD).
    Stepanova M; Rafiq N; Makhlouf H; Agrawal R; Kaur I; Younoszai Z; McCullough A; Goodman Z; Younossi ZM
    Dig Dis Sci; 2013 Oct; 58(10):3017-23. PubMed ID: 23775317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Final results of a long-term, clinical follow-up in fatty liver patients.
    Dam-Larsen S; Becker U; Franzmann MB; Larsen K; Christoffersen P; Bendtsen F
    Scand J Gastroenterol; 2009; 44(10):1236-43. PubMed ID: 19670076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-alcoholic fatty liver disease and the metabolic syndrome in an urban hospital serving an African community.
    Onyekwere CA; Ogbera AO; Balogun BO
    Ann Hepatol; 2011; 10(2):119-24. PubMed ID: 21502672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver failure caused by non-alcoholic steatohepatitis in an obese young male.
    Suzuki D; Hashimoto E; Kaneda K; Tokushige K; Shiratori K
    J Gastroenterol Hepatol; 2005 Feb; 20(2):327-9. PubMed ID: 15683446
    [No Abstract]   [Full Text] [Related]  

  • 15. [Consequences of non-alcoholic fatty liver disease still unclear].
    Jansen PL
    Ned Tijdschr Geneeskd; 2012; 156(9):A4568. PubMed ID: 22373558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-alcoholic fatty liver disease: further expression of the metabolic syndrome.
    Tarantino G; Saldalamacchia G; Conca P; Arena A
    J Gastroenterol Hepatol; 2007 Mar; 22(3):293-303. PubMed ID: 17295757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Non alcoholic steatohepatitis: the future in hepatology?].
    Mathurin P
    Gastroenterol Clin Biol; 2002 May; 26(5):471-2. PubMed ID: 12122356
    [No Abstract]   [Full Text] [Related]  

  • 18. In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not.
    Younossi ZM; Otgonsuren M; Venkatesan C; Mishra A
    Metabolism; 2013 Mar; 62(3):352-60. PubMed ID: 22999011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relevance of liver histology to predicting clinically meaningful outcomes in nonalcoholic steatohepatitis.
    Pagadala MR; McCullough AJ
    Clin Liver Dis; 2012 Aug; 16(3):487-504. PubMed ID: 22824477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Coffee - a stimulant for the liver].
    MMW Fortschr Med; 2014 Apr; 156(8):6. PubMed ID: 24851424
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.